The role of the mammalian target of rapamycin (mTOR) in renal disease

Journal of the American Society of Nephrology

Volumn 20, Issue 12, 2009, Pages 2493-2502

  Lieberthal, Wilfred ^a,b   Levine, Jerrold S ^c,d  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b Northport Veterans Administration   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; FRACTALKINE; INTERLEUKIN 2; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYCYSTIN 1; RANTES; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASOPRESSIN 2 RECEPTOR ANTAGONIST; VASOPRESSIN ANTAGONIST; VON HIPPEL LINDAU PROTEIN;

ACUTE KIDNEY FAILURE; CANCER SURVIVAL; CELL DIVISION; CELL PROLIFERATION; CELL SIZE; CELL SURVIVAL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; FIBROSING ALVEOLITIS; GENE MUTATION; GLOMERULUS FILTRATION RATE; HEYMANN NEPHRITIS; HUMAN; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY HYPERTROPHY; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY;

EID: 72049105867     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008111186     Document Type: Short Survey

References (123)

1. Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31: 335-340, 1998
2. Sehgal SN: Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 35: 7S-14S, 2003
3. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004
4. Fingar DC, Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004
5. Abraham RT: Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 10: 330-336, 1998
6. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175, 2002 (Pubitemid 34876545)
7. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302, 2004 (Pubitemid 38991819)
8. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128, 2004 (Pubitemid 39468014)
9. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006
10. Arsham AM, Neufeld TP: Thinking globally and acting locally with TOR. Curr Opin Cell Biol 18: 589-597, 2006
11. Lee CH, Inoki K, Guan KL: mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 47: 443-467, 2007 (Pubitemid 46272135)
12. Dickson LM, Lingohr MK, McCuaig J, Hugl SR, Snow L, Kahn BB, Myers MG, Jr., Rhodes CJ: Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J Biol Chem 276: 21110-21120, 2001 (Pubitemid 37413097)
13. Avruch J, Lin Y, Long X, Murthy S, Ortiz-Vega S: Recent advances in the regulation of the TOR pathway by insulin and nutrients. Curr Opin Clin Nutr Metab Care 8: 67-72, 2005 (Pubitemid 40204447)
14. Chiu T, Santiskulvong, Rosengurt E: EGF receptor transactivation mediates ANG II-stimulated mitogensis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathways. Am J Physiol Gastrointest Liver Physiol 288: G182-G194, 2005
15. Navolanic PM, Steelman LS, McCubrey JA: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 22: 237-252, 2003
16. Beugnet A, Tee AR, Taylor PM, Proud CG: Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J 372: 555-566, 2003 (Pubitemid 36723901)
17. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer JM, Natt F, Bos JL, Zwartkruis FJ, Thomas G: Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 102: 14238-14243, 2005 (Pubitemid 41429682)
18. Hardie DG, Carling D, Carlson M: The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell? Annu Rev Biochem 67: 821-855, 1998 (Pubitemid 28411146)
19. Hardie DG: AMP-activated protein kinase: The guardian of cardiac energy status. J Clin Invest 114: 465-468, 2004 (Pubitemid 39572094)
20. Hardie DG, Hawley SA, Scott JW: AMP-activated protein kinase: Development of the energy sensor concept. J Physiol 574: 7-15, 2006 (Pubitemid 43905792)
21. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675, 2001 (Pubitemid 33096187)
22. Harrington LS, Findlay GM, Lamb RF: Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30: 35-42, 2005
23. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657, 2002 (Pubitemid 34993700)
24. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003 (Pubitemid 37506046)
25. Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834, 2003
26. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J: Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb Curr Biol 13: 1259-1268, 2003
27. Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG: The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 280: 18717-18727, 2005
28. Tee AR, Anjum R, Blenis J: Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem 278: 37288-37296, 2003
29. Brazil DP, Yang ZZ, Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242, 2004
30. Potter CJ, Pedraza LG, Xu T: Akt regulates growth by directly phosphorylating TSC2. Nat Cell Biol 4: 658-665, 2002
31. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005
32. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137, 2006 (Pubitemid 44466632)
33. Polak P: mTORC2 caught in a SINful Akt. Dev Cell 11: 433-434, 2006
34. Hresko RC, Mueckler M: mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406-40416, 2005
35. Reiter AK, Bolster DR, Crozier SJ, Kimball SR, Jefferson LS: Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside. Am J Physiol Endocrinol Metab 288: E980-988, 2005
36. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472-1487, 2002 (Pubitemid 34686329)
37. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216, 2004 (Pubitemid 38010048)
38. Gingras AC, Raught B, Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001
39. Gingras AC, Raught B, Sonenberg N: mTOR signaling to translation. Curr Top Microbiol Immunol 279: 169-197, 2004
40. Sataranatarajan K, Mariappan MM, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS: Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin. Am J Pathol 171: 1733-1742, 2007
41. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G: Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16: 3693-3704, 1997 (Pubitemid 27250062)
42. Holz MK, Ballif BA, Gygi SP, Blenis J: mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123: 569-580, 2005
43. Nigam S, Lieberthal W: Acute renal failure: III. The role of growth factors in the process of renal regeneration and repair. Am J Physiol Renal Physiol 279: F3-F11, 2000 (Pubitemid 30619542)
44. Megyesi J, Andrade L, Vieira JM Jr, Safirstein RL, Price PM: Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure. Am J Physiol Renal Physiol 283: F810-F816, 2002 (Pubitemid 35033969)
45. Witzgall R, Brown D, Schwarz C, Bonventre JV: Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney: Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells J Clin Invest 93: 2175-2188, 1994 (Pubitemid 24978965)
46. Bonventre JV: Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 14[Suppl 1]: S55-S61, 2003 (Pubitemid 36687041)
47. Camardo J: The rapamune era of immunosuppression 2003: The journey from the laboratory to clinical transplantation. Transplant Proc 35: 18S-24S, 2003
48. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS: Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281: F693-F706, 2001 (Pubitemid 32946736)
49. Lieberthal W, Fuhro R, Andry C, Patel V, Levine JS: Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance. Transplantation 82: 17-22, 2006 (Pubitemid 44296972)
50. Smith KD, Wrenshall LE, Nicosia RF, Pichler R, Marsh CL, Alpers CE, Polissar N, Davis CL: Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 14: 1037-1045, 2003 (Pubitemid 36359286)
51. McTaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlanovich S, Feng S: Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3: 416-423, 2003 (Pubitemid 36560092)
52. Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S: Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 76: 1594-1599, 2003 (Pubitemid 37549833)
53. Goncalves GM, Cenedeze MA, Feitoza CQ, de Paula CB, Marques GD, Pinheiro HS, de Paula Antunes Teixeira V, Antonia dos Reis M, Pacheco-Silva A, Camara NO: The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury. Transplant Proc 39: 417-420, 2007
54. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B: Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-1042, 1999
55. Loverre A, Ditonno P, Crovace A, Gesualdo L, Ranieri E, Pontrelli P, Stallone G, Infante B, Schena A, Di Paolo S, Capobianco C, Ursi M, Palazzo S, Battaglia M, Selvaggi FP, Schena FP, Grandaliano G: Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: Differential modulation by rapamycin. J Am Soc Nephrol 15: 2675-2686, 2004 (Pubitemid 41103374)
56. Estacio RO, Schrier RW: Diabetic nephropathy: Pathogenesis, diagnosis, and prevention of progression. Adv Intern Med 46: 359-408, 2001 (Pubitemid 33791972)
57. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW: Nephropathy in diabetes. Diabetes Care 27[Suppl 1]: S79-S83, 2004
58. Wilson PD: Polycystic kidney disease. N Engl J Med 350: 151-164, 2004
59. Hostetter TH: Progression of renal disease and renal hypertrophy. Annu Rev Physiol 57: 263-278, 1995
60. Hostetter TH: Hyperfiltration and glomerulosclerosis. Semin Nephrol 23: 194-199, 2003
61. Chen JK, Chen J, Neilson EG, Harris RC: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16: 1384-1391, 2005 (Pubitemid 41716522)
62. Kasinath BS, Mariappan MM, Sataranatarajan K, Lee MJ, Feliers D: mRNA translation: Unexplored territory in renal science. J Am Soc Nephrol 17: 3281-3292, 2006 (Pubitemid 44865271)
63. Mariappan MM, Feliers D, Mummidi S, Choudhury GG, Kasinath BS: High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes 56: 476-485, 2007 (Pubitemid 46263079)
64. Canabal DD, Potian JG, Duran RG, McArdle JJ, Routh VH: Hyperglycemia impairs glucose and insulin regulation of nitric oxide production in glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol 293: R592-R600, 2007 (Pubitemid 47205039)
65. Yeshao W, Gu J, Peng X, Nairn AC, Nadler JL: Elevated glucose activates protein synthesis in cultured cardiac myocytes. Metabolism 54: 1453-1460, 2005 (Pubitemid 41527014)
66. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007 (Pubitemid 350145909)
67. Inoki K: Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract 82[Suppl 1]: S59-S62, 2008
68. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G: mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57: 945-957, 2008
69. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS: A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 292: F617-F627, 2007 (Pubitemid 46220529)
70. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A: Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 340: 296-301, 2006 (Pubitemid 41827680)
71. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J: Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27: 495-502, 2007 (Pubitemid 47482007)
72. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17: 1395-1404, 2006 (Pubitemid 43673420)
73. Lock HR, Sacks SH, Robson MG: Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Renal Physiol 292: F76-F81, 2007 (Pubitemid 46105245)
74. Shegogue D, Trojanowska M: Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 279: 23166-23175, 2004 (Pubitemid 38685622)
75. Brenneisen P, Wenk J, Wlaschek M, Krieg T, Scharffetter-Kochanek K: Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. J Biol Chem 275: 4336-4344, 2000 (Pubitemid 30094675)
76. Harris RC, Neilson EG: Toward a unified theory of renal progression. Annu Rev Med 57: 365-380, 2006 (Pubitemid 43261996)
77. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004
78. Lamouille S, Derynck R: Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178: 437-451, 2007 (Pubitemid 47196152)
79. Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS: p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res 68: 6524-6532, 2008
80. Eddy AA, Neilson EG: Chronic kidney disease progression. J Am Soc Nephrol 17: 2964-2966, 2006
81. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69: 2029-2036, 2006 (Pubitemid 43924267)
82. Diekmann F, Rovira J, Carreras J, Arellano EM, Banon-Maneus E, Ramirez-Bajo MJ, Gutierrez-Dalmau A, Brunet M, Campistol JM: Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 18: 2653-2660, 2007 (Pubitemid 47531192)
83. Lieberthal W: Biology of ischemic and toxic renal tubular cell injury: Role of nitric oxide and the inflammatory response. Curr Opin Nephrol Hypertens 7: 289-295, 1998
84. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-2072, 2005 (Pubitemid 41716437)
85. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Grone HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM: Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol 170: 301-315, 2007 (Pubitemid 47339209)
86. Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H: Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 294: F440-F449, 2008 (Pubitemid 351199410)
87. Igarashi P, Somlo S: Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 13: 2384-2398, 2002 (Pubitemid 34925250)
88. Sutters M, Germino GG: Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology. J Lab Clin Med 141: 91-101, 2003 (Pubitemid 36216561)
89. Ong AC, Harris PC: Molecular pathogenesis of ADPKD: The polycystin complex gets complex. Kidney Int 67: 1234-1247, 2005
90. Aguiari G, Trimi V, Bogo M, Mangolini A, Szabadkai G, Pinton P, Witzgall R, Harris PC, Borea PA, Rizzuto R, del Senno L: Novel role for polycystin-1 in modulating cell proliferation through calcium oscillations in kidney cells. Cell Prolif 41: 554-573, 2008 (Pubitemid 351692945)
91. Edelstein CL: Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol 3: 1219-1226, 2008
92. Tao Y, Zafar I, Kim J, Schrier RW, Edelstein CL: Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol 19: 749-755, 2008
93. Gattone VH 2nd: Emerging therapies for polycystic kidney disease. Curr Opin Pharmacol 5: 535-542, 2005
94. Thibonnier M, Coles P, Thibonnier A, Shoham M: The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 41: 175-202, 2001 (Pubitemid 32385887)
95. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, et al.: Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105: 787-791, 1992
96. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005 (Pubitemid 41710293)
97. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004 (Pubitemid 38508512)
98. Tao Y, Kim J, Yin Y, Zafar I, Falk S, He Z, Faubel S, Schrier RW, Edelstein CL: VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int 72: 1358-1366, 2007 (Pubitemid 350126784)
99. Cowley BD Jr, Smardo FL Jr, Grantham JJ, Calvet JP: Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease. Proc Natl Acad Sci U S A 84: 8394-8398, 1987
100. Harding MA, Gattone VH 2nd, Grantham JJ, Calvet JP: Localization of overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse. Kidney Int 41: 317-325, 1992
101. Trudel M, D'Agati V, Costantini F: C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 39: 665-671, 1991
102. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic disease. J Am Soc Nephrol 16: 46-51, 2005 (Pubitemid 43073155)
103. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006 (Pubitemid 43372904)
104. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103:5466-5471, 2006
105. Edelstein CL: Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol News Issues 22: 25-26, 2008
106. Torra R: New therapeutic prospects in autosomal dominant polycystic kidney disease. Nefrologia 28: 257-262, 2008
107. Patel PH, Chaganti RS, Motzer RJ: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94: 614-619, 2006 (Pubitemid 43361889)
108. Clark PE: Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 17: 331-336, 2007 (Pubitemid 47344620)
109. Prenen H, Gil T, Awada A: New therapeutic developments in renal cell cancer. Crit Rev Oncol Hematol 69: 56-63, 2009
110. Board RE, Thistlethwaite FC, Hawkins RE: Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev 33: 1-8, 2007 (Pubitemid 46132000)
111. Ma WW, Jimeno A: Temsirolimus. Drugs Today (Barc) 43: 659-669, 2007
112. Costa LJ, Drabkin HA: Renal cell carcinoma: New developments in molecular biology and potential for targeted therapies. Oncologist 12: 1404-1415, 2007
113. Garcia JA, Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347-1354, 2008
114. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014, 2002
115. Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578, 1999
116. Hockel M, Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol 28: 36-41, 2001
117. Ivan M, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 11: 27-34, 2001 (Pubitemid 32119274)
118. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS: Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13: 7388-7393, 2007
119. Kondo K, Yao M, Kobayashi K, Ota S, Yoshida M, Kaneko S, Baba M, Sakai N, Kishida T, Kawakami S, Uemura H, Nagashima Y, Nakatani Y, Hosaka M: PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 91: 219-224, 2001 (Pubitemid 32041743)
120. Kenerson HL, Aicher LD, True LD, Yeung RS: Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62: 5645-5650, 2002
121. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4: 147-158, 2003 (Pubitemid 37045363)
122. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66: 5549-5554, 2006 (Pubitemid 43927103)
123. Lee M, Hwang JT, Lee HJ, Jung SN, Kang I, Chi SG, Kim SS, Ha J: AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 278: 39653-39661, 2003 (Pubitemid 37248526)